Skip to content

Comparison of ropivacaine, ropivacaine-morphine, ropivacaine-dexmedetomidine for interscalene brachial plexus block: A prospective, randomized, double-blinded, comparative study

Comparison of ropivacaine, ropivacaine-morphine, ropivacaine-dexmedetomidine for interscalene brachial plexus block: A prospective, randomized, double-blinded, comparative study

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16007688
Enrollment
Unknown
Registered
2016-01-01
Start date
2016-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Comparison of ropivacaine, ropivacaine-morphine, ropivacaine-dexmedetomidine for interscalene brachial plexus block: A prospective, randomized, double-blinded, comparative study

Interventions

ropivacaine mixed with dexmedetomidine group:ropivacaine mixed with dexmedetomidine
and ropivacaine mixed with morphine group:ropivacaine mixed with morphine

Sponsors

The Second Affiliated Hospital of Wenzhou Medical College
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 90 patients with American Society of Anesthesiologists (ASA) physical status I/II who were scheduled for upper extremity surgery under brachial plexus block was to be used were enrolled in this prospective, doubleblind, controlled trial.

Exclusion criteria

Exclusion criteria: (1) to test suspected drug allergy; (2) in patients weighing more than 100kg; (3) preoperative New York Heart Association (NYHA) class III or IV persons; (4) Consolidated heart, liver, kidney, hematopoietic system and other vital organs and systems of serious primary disease or ALT, more than 2 times of the upper limit of normal AST level, Cr exceeds the upper limit of normal level; (5) preoperative hemoglobin 160g/L, or hematocrit <30% significantly; preoperative platelet count <=100* 10^9/L persons; preoperative coagulation prompt PT or APTT greater than the upper limit of normal by 1.5 times; (6) Liquid overload, including pulmonary edema; (7) serum K+, Na+, Mg2+, Cl- abnormalities; (8) with severe systemic infection; (9) associated with neurological and psychiatric disorders while not cooperate or unwilling collaborators; (10) during pregnancy, lactation or recent fertility planner; (11) within the past three months those who participated in other clinical trials; (12) The researchers consider it appropriate to participate in the clinical trial were.

Design outcomes

Primary

MeasureTime frame
Onset time of sensory block;Duration of sensory block;Onset time of motor block;Duration of motor block;

Countries

China

Contacts

Public ContactWang Xiaocou
wangxiaocou@qq.com+86 13566236456

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026